Iktos articles

Abstract
Generative models are frequently used for de novo design in drug discovery projects to propose new molecules. However, the question of whether or not the generated molecules can be synthesized is not systematically taken into account during generation, even though being able to synthesize the generated molecules is a fundamental requirement for such methods to be useful in practice. Methods have been developed to estimate molecule synthesizability, but, so far,

Plentiful financing and multiple pharma partnerships illustrate the burgeoning interest in applying artificial intelligence tools to drug research and development.

In April of this year, the German biotechnology company Evotec announced a phase 1 clinical trial on a new anticancer molecule. The candidate was created in partnership with Exscientia, a company based in Oxford, UK, that applies artificial intelligence (AI) techniques to small-molecule drug discovery.

A Technology Platform for Deep-Learning-Based de novo Drug Design
Digital tools are a key to shortening the development of active pharmaceutical ingredients and thus market-ready drugs and therapies. Big data and artificial intelligence (AI) can significantly accelerate many processes and make them more efficient. The Paris, Francebased start-up Iktos is developing a proprietary AI technology for ligand and structure-based de novo drug design, focusing on multi parametri

Iktos Develops a Technology Platform for Deep Learning-Based de novo Drug Development

Digital tools are a key to shortening the development of active pharmaceutical ingredients and thus market-ready drugs and therapies.